Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | SHBG | P04278 | 2/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.70 |
| ▸ | G6PD | P11413 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362889 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL11004575 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL1799883 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL15463390 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL20058395 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL4890316 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL6938662 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL1800894 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL14525640 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL4893508 | 1.00 | GPBAR1 (0.70) | GPBAR1LMNACYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230085402-A1 | BIOMARKERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-03-16 | — | — | US | claimed |
| US-20130234071-A1 | COMPOSITION OF HUMAN SYNTHETIC URINE | DENEAU JOEL DAVID (US) | 2013-09-12 | — | — | US | claimed |
| EP-4292102-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2023-12-20 | — | — | EP | disclosed |
| US-20230085402-A1 | BIOMARKERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| WO-2022171680-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-08-18 | — | — | WO | disclosed |
| US-11046728-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10981946-B2 | Methods for the purification of deoxycholic acid | ALLERGAN SALES, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3021852-B1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200095274-A1 | METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID | ALLERGAN SALES, LLC (US) | 2020-03-26 | — | — | US | disclosed |
| US-10495653-B2 | Stabilization of labile analytes in reference materials | BIO-RAD LABORATORIES, INC. (US) | 2019-12-03 | — | — | US | disclosed |
| US-10472384-B2 | Methods for the purification of deoxycholic acid | ALLERGAN SALES, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2015010054-A2 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20140329263-A1 | Stabilization of Labile Analytes in Reference Materials | BIO-RAD LABORATORIES, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20130137884-A1 | METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID | Kythera Biopharmaceuticals ,Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137884-A1 | METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID | Kythera Biopharmaceuticals ,Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011075701-A2 | METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID | KYTHERA BIOPHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20080033046-A1 | Treatment of myocardial infarction with 11HSD1 inhibitors | UNIVERSITY OF EDINBURGH (GB) | 2008-02-07 | — | — | US | disclosed |
| US-20060019400-A1 | Method for the determination of glucuronides in physiological samples | UNIVERSITY OF MARYLAND (US) | 2006-01-26 | — | — | US | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033046-A1 | Treatment of myocardial infarction with 11HSD1 inhibitors | HSD11B1, HSD11B2, CYP11B1 | GPBAR1 533/4885LMNA 4376/4885CYP3A4 145/4885 |
| US-20130137884-A1 | METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID | HSD11B1, HSD17B7, HSD17B13 | GPBAR1 98/4885LMNA 2134/4885CYP3A4 336/4885 |
| US-20200095274-A1 | METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID | HSD11B1, HSD17B7, HSD17B13 | GPBAR1 110/4885LMNA 2195/4885CYP3A4 280/4885 |
| US-10472384-B2 | Methods for the purification of deoxycholic acid | HSD11B1, HSD17B7, HSD17B13 | GPBAR1 110/4885LMNA 2195/4885CYP3A4 280/4885 |
| US-10981946-B2 | Methods for the purification of deoxycholic acid | HSD11B1, HSD17B7, HSD17B13 | GPBAR1 110/4885LMNA 2195/4885CYP3A4 280/4885 |
| US-11046728-B2 | Neuroactive steroids, compositions, and uses thereof | ADRA1B, AVPR1B, ADRA2B | GPBAR1 177/4885LMNA 3004/4885CYP3A4 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.